Knight Therapeutics Reports Third Quarter 2026 Results
Achieved nine-month record-high revenues of over $430 million and Adjusted EBITDA1 of over $76 milli
Achieved nine-month record-high revenues of over $430 million and Adjusted EBITDA1 of over $76 milli